Neurosense Therapeutics Ltd. NRSN 深 沪
已收盘 03-27 16:00:00 美东时间
0.731
-0.039
-5.06%
华盛通- 最 高0.7937
- 今 开0.76
- 成交量 11.68万股
- 最 低 0.7302
- 昨 收 0.77
- 总市值 2441.29万
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 0.63
- 委 比 78.21%
- 总股本 3339.66万
- 历史最高 8.18
- 量 比 0.56
- 振 幅 8.25%
- 历史最低 0.40
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks
NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks NeuroSense rescheduled its pre-New Drug Submission meeting with Health Canada to May 2026 to include additional clinical, biomarker, and survival analyses for PrimeC. Clinical and biomarker results from NeuroS
03-24 21:03
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.
03-10 18:40
NeuroSense Therapeutics Announces Availability Of Additional Long-Term Survival Data From PARADIGM Phase 2b Clinical Trial Evaluating PrimeC In Patients With ALS
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the
02-18 22:14
NeuroSense Therapeutics Granted Australia Patent For Its PrimeC
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian
02-09 22:23
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biote...
02-09 22:20
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- Neuro...
01-21 21:30
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical sta...
01-08 21:45
NeuroSense Therapeutics' Analysis From Phase 2 NST-AD-001 Trial Of PrimeC Combination In Alzheimer's Demonstrates Favorable Tolerability For PrimeC
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of the safety
2025-12-22 22:20
NeuroSense Completes Data Collection for Alzheimer’s Trial
Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an update. NeuroSense Th...
2025-12-08 21:27
